The study is open label, which means the treatment is known and no hidden treatment is used. It is designed for people who finished a previous remibrutinib study and were thought to be doing well enough to continue treatment. During the trial, remibrutinib is taken over a longer period of time, and health is watched for any side effects, including common adverse events and more serious serious adverse events.

Participants in the study will receive either Barzolvolimab or a placebo, which is a substance that looks like the medication but does not contain any active ingredients. The study will last for several weeks, during which participants will receive regular doses of the medication or placebo. Throughout the study, participants will be monitored to assess changes in their urticaria symptoms, particularly focusing on the reduction of hives and itching. The main goal is to see if Barzolvolimab can significantly improve the condition compared to the placebo by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The trial will also involve regular check-ups and assessments to track the progress and any potential side effects. The findings from this study could provide valuable insights into the effectiveness of Barzolvolimab as a treatment option for those suffering from Chronic Spontaneous Urticaria.

Participants in this study will receive either lesigercept or a placebo through a subcutaneous injection, which is a method of delivering medication via a needle into the fatty layer of tissue just beneath the skin. The study is designed so that neither the participants nor the researchers know which substance is being administered at any given time. Over a period of time, the way the medication affects the frequency and severity of the hives will be observed to determine if it is a safe and effective option for managing the disease.

Participants in this study are individuals who have previously taken part in other clinical trials involving the medication. During this phase, participants may be placed in an observation group to monitor their condition over time, or they may receive retreatment with barzolvolimab. The study follows participants for up to 52 weeks to observe how well the disease is controlled and to monitor for any adverse events, which are unintended or harmful medical occurrences that may happen during the course of treatment.

During the study, participants are assigned to receive either ritlecitinib or a placebo. The study is organized in two stages. The first stage lasts for 12 weeks, after which a second stage, known as an extension period, also lasting 12 weeks, begins. All participants in this phase will follow the same treatment process to see how the medicine affects the severity of the hives over time.

The study uses two different strengths of the nasal spray – 0.5 mg and 1 mg of epinephrine. Participants will receive both the active medication and placebo at different times during the study, allowing researchers to compare the effectiveness of each treatment. The medication is administered as a nasal spray, which means it is sprayed into the nose.

During the study, participants will use a smartphone application to record their symptoms and any side effects they experience. They will track how quickly their symptoms improve after using the spray and whether the symptoms return within 24 hours. The study will measure changes in both itching and hive severity, as well as monitor the safety of the treatment.

The study will examine if tildrakizumab, which is an anti-IL-23 antibody (a type of protein that affects the immune system), can reduce the severity of hives and itching in people with this condition. During the study, participants will receive injections of the medication over a period of 16 weeks, with each dose containing up to 200 mg of the medicine.

The main goal is to measure how the severity of urticaria symptoms changes after treatment with the medication. Participants will be monitored for improvements in their symptoms, including the frequency and intensity of hives and itching, as well as their overall quality of life. The study will also track how long any improvements in symptoms last after the treatment period ends.

The purpose of the study is to assess how effective and safe EVO756 Potassium is at different dose levels. The study will last for up to 12 weeks, during which participants will take the medication orally. Throughout the study, participants will be monitored to see how their symptoms change over time. The study aims to find out if EVO756 Potassium can reduce the severity of the hives and improve the quality of life for those affected by this condition.

Participants will be asked to keep track of their symptoms and report any changes they experience. The study will help determine the best dose of EVO756 Potassium and provide valuable information on its potential as a treatment for Chronic Spontaneous Urticaria. This research is important for developing new ways to manage and treat this challenging condition.

The purpose of the study is to determine the safety of INF904 when taken in multiple doses by people with moderate to severe CSU or HS. Participants will take the medication over a period of time, and researchers will monitor them to see how their bodies respond to the treatment. This includes looking at how the medication is absorbed and processed in the body, which is known as pharmacokinetics. The study will also track any side effects or adverse events that occur during the trial.

Participants in the study will be asked to take the medication as directed and attend regular check-ups with the research team. These visits will help ensure that the treatment is working as intended and that any potential side effects are managed. The study aims to provide valuable information on the safety and effectiveness of INF904 for people living with CSU or HS, potentially leading to better treatment options in the future.

The purpose of this research is to assess how well remibrutinib works over an extended period in patients who have already participated in previous studies of this medication. During the study, patients who showed improvement in their symptoms will either continue taking remibrutinib or switch to placebo. The researchers will monitor how long it takes for symptoms to return, if they do.

Throughout the study, participants may also receive other common treatments for their condition, including antihistamines (medications that reduce allergic symptoms) and corticosteroids (medications that reduce inflammation). The study will track any side effects that occur during the treatment period. The total duration of treatment may last up to 160 weeks, depending on the participant’s response to the medication.

The purpose of the study is to determine if BP11 works as well as Xolair in treating patients with this type of chronic hives. Participants in the study will receive either BP11, Xolair, or a placebo, which is an inactive substance. The study will last for several months, during which participants will receive regular injections and attend scheduled visits to monitor their condition and any changes in their symptoms. The study will also assess the safety of the treatments by monitoring any side effects or reactions that may occur.

Throughout the study, participants will be asked to keep a diary of their symptoms and any changes they experience. This information will help researchers understand how well the treatments are working and if there are any differences between them. The study will also involve regular check-ups, including physical exams and laboratory tests, to ensure the safety and well-being of the participants. The ultimate goal is to find an effective treatment option for those who suffer from Chronic Spontaneous Urticaria and have not found relief with current medications.

Participants in the study will receive Danicopan in the form of a film-coated tablet taken orally. The study will compare the effects of Danicopan on patients with different levels of a protein in the blood called IgE, which is often linked to allergic reactions. The trial will last for about 17 weeks, during which the changes in the severity of the hives will be monitored. The study will also look at how the treatment affects the quality of life of the participants and their use of other medications for relief.

In addition to Danicopan, participants will need to be vaccinated against Neisseria meningitidis, a type of bacteria that can cause serious infections. This is because the study involves treatments that might affect the immune system. The trial will help researchers understand if Danicopan is a safe and effective option for people with chronic spontaneous urticaria who have not found relief with other treatments.

The purpose of the study is to evaluate how effective and safe Barzolvolimab is in reducing the activity of urticaria. Participants in the study will receive either the treatment or a placebo and will be monitored over a period of time to assess changes in their symptoms. The study will involve regular check-ups and assessments to track the progress of the condition and the effects of the treatment.

Throughout the study, participants will be asked to keep a daily diary of their symptoms and attend scheduled visits to monitor their health and the impact of the treatment. The main goal is to see if Barzolvolimab can significantly reduce the severity of urticaria symptoms by the end of the study period, which is set at 12 weeks. This research aims to provide new insights into managing Chronic Spontaneous Urticaria for those who have not responded well to existing treatments.

The purpose of the study is to determine if remibrutinib is more effective than a placebo in reducing the symptoms of CSU, such as itching and hives, over a period of 52 weeks. Participants in the study will be randomly assigned to receive either remibrutinib, a placebo, or omalizumab. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. Throughout the study, participants will be monitored for any changes in their symptoms and any side effects they may experience.

This trial is important for understanding how well remibrutinib works in treating CSU, especially in patients who have not responded well to other treatments like second-generation H1-antihistamines. The study will help determine if remibrutinib can provide a new option for managing this challenging condition. Participants will be required to keep a daily diary of their symptoms to help researchers assess the effectiveness of the treatment. The study will last for a total of 52 weeks, with regular check-ins to monitor progress and any potential side effects.

The purpose of the study is to evaluate how effective remibrutinib is in treating CSU in adolescents aged 12 to less than 18 years who have not responded well to standard treatments known as H1-antihistamines. These are medications that help reduce allergy symptoms by blocking the action of histamine, a substance in the body that causes allergic reactions. Participants in the study will take the medication or placebo for 24 weeks, and their symptoms will be monitored to see if there is an improvement. After this period, there is an option for participants to continue in an open-label extension, where they will receive remibrutinib for up to three more years, and a long-term follow-up period for safety monitoring.

Throughout the study, researchers will assess changes in the severity of the hives and itching, as well as monitor any side effects or changes in health. The study aims to provide valuable information on the safety and effectiveness of remibrutinib for treating CSU in young people, potentially offering a new option for those who do not find relief with current treatments.

The purpose of the study is to assess how well Povorcitinib works in reducing the symptoms of CSU. Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will be conducted over a period of time, during which participants will take the medication and have regular check-ups to monitor their condition and any changes in their symptoms.

Throughout the study, participants will be asked to keep a daily electronic diary to record their symptoms and any side effects they experience. This information will help researchers understand how Povorcitinib affects CSU and whether it can help control the symptoms of this condition. The study aims to provide valuable insights into the potential benefits of Povorcitinib for people living with Chronic Spontaneous Urticaria.

Participants in the study will receive omalizumab injections, and the intervals between these injections will be adjusted to see if longer periods between doses are effective. The study will monitor the control of urticaria symptoms over a period of time to ensure that extending the treatment intervals does not lead to a loss of symptom control. The trial aims to provide insights into whether patients can maintain their quality of life with fewer injections.

The study is designed to be open-label, meaning that both the participants and the researchers will know which treatment is being administered. This approach helps in closely monitoring the effects of extending the treatment intervals. The trial will last for a total of 36 weeks, during which the participants’ symptoms and overall health will be regularly assessed to ensure their well-being and the effectiveness of the treatment strategy.

The purpose of the study is to evaluate the safety and tolerability of Briquilimab in adults who continue to experience symptoms of Chronic Spontaneous Urticaria despite treatment with other medications, such as antihistamines or omalizumab. Participants will receive doses of Briquilimab and will be monitored for any side effects or changes in their condition. The study will help determine how well the medication works in reducing the symptoms of itchy skin and hives.

Throughout the study, participants will attend regular visits to track their progress and report any changes in their symptoms. They will also be asked to keep a daily diary of their symptoms and any side effects they experience. The trial aims to provide valuable information on the potential benefits of Briquilimab for those suffering from Chronic Spontaneous Urticaria and to explore its overall safety for future use.

The purpose of the study is to evaluate how well EP262 works in reducing the itchiness and number of hives in people with CSU. The study will take place over a period of six months, during which participants will take the medication in capsule form. Throughout the study, participants will be monitored for any changes in their symptoms and any side effects they might experience. The study aims to provide valuable information on the safety and effectiveness of EP262 for treating CSU.

Participants will be asked to visit the study site regularly for check-ups and assessments. These visits will help researchers gather data on the intensity of itching, the number of hives, and any changes in health indicators such as vital signs and laboratory tests. The study is designed to ensure that all participants are closely monitored to maintain their safety and well-being while contributing to the understanding of how EP262 can help manage Chronic Spontaneous Urticaria.